Cargando…

SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor

Detalles Bibliográficos
Autores principales:	Foti, Rosario, Amato, Giorgio, Visalli, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328605/ https://www.ncbi.nlm.nih.gov/pubmed/32744241 http://dx.doi.org/10.1016/j.mehy.2020.110040

Ejemplares similares

Telemedicine in the Management of Patients with Rheumatic Disease during COVID-19 Pandemic: Incidence of Psychiatric Disorders and Fibromyalgia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Foti, Rosario, et al.
Publicado: (2022)

Management of Patients With Inflammatory Rheumatic Diseases: Telemedicine and Rheumatologists Challenged in the Era of COVID-19
por: Foti, Rosario, et al.
Publicado: (2020)

Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
por: Joven, Beatriz, et al.
Publicado: (2023)

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
por: Sánchez-Rodríguez, Guillermo, et al.
Publicado: (2023)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis
por: Liu, Ningyuan, et al.
Publicado: (2021)

The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis
por: Maeda, Shinji, et al.
Publicado: (2012)

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
por: Fragoulis, George E., et al.
Publicado: (2022)

Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
por: Ramonda, Roberta, et al.
Publicado: (2021)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

Psoriatic lesional expression of SARS-CoV-2 receptor ACE2 is reduced by blockade of IL-17 signaling but not by other biologic treatments
por: Peng, Ge, et al.
Publicado: (2022)

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
por: Becciolini, Andrea, et al.
Publicado: (2023)

CXCL4 is a novel inducer of human Th17 cells and correlates with IL‐17 and IL‐22 in psoriatic arthritis
por: Affandi, Alsya J., et al.
Publicado: (2018)

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
por: Sakkas, Lazaros I., et al.
Publicado: (2019)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen
por: Foti, Rosario, et al.
Publicado: (2016)

Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis
por: Rahmati, Sara, et al.
Publicado: (2020)

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
por: van Baarsen, Lisa GM, et al.
Publicado: (2014)

Dual inhibition of IL-17A and IL-17F in psoriatic disease
por: Iznardo, Helena, et al.
Publicado: (2021)

Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2020)

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?
por: Benucci, Maurizio, et al.
Publicado: (2022)

Cutaneous Eruption after SARS-CoV-2 Vaccine in Psoriatic Patient Treated with Methotrexate
por: Serena, Lembo, et al.
Publicado: (2022)

Functional role of IL-22 in psoriatic arthritis
por: Mitra, Anupam, et al.
Publicado: (2012)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
por: Boutet, Marie-Astrid, et al.
Publicado: (2018)

Clinical and Histopathological Features of Scleroderma-like Disorders: An Update
por: Foti, Rosario, et al.
Publicado: (2021)

Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States
por: Pizzicato, Lia N, et al.
Publicado: (2023)

Impact of Sars‐CoV‐2 pandemic on psoriatic patients
por: Biondi, Gabriele, et al.
Publicado: (2022)

Mannan-induced Nos2 in macrophages enhances IL-17–driven psoriatic arthritis by innate lymphocytes
por: Zhong, Jianghong, et al.
Publicado: (2018)

Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?
por: Zafiriou, Efterpi, et al.
Publicado: (2021)

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
por: Lupia, Tommaso, et al.
Publicado: (2022)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011)

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
por: G.S. Saad, Carla, et al.
Publicado: (2023)

A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile
por: Bautista-Herrera, LA, et al.
Publicado: (2020)

Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
por: Wang, Jiao, et al.
Publicado: (2023)

Oral Candida Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature
por: Pettas, Efstathios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2e1ddd7qluft9sm6tdsvsaqrpf